Kenvue Inc. (NYSE:KVUE) Shares Sold by Bahl & Gaynor Inc.

Bahl & Gaynor Inc. trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE) by 2.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 256,248 shares of the company’s stock after selling 6,744 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Kenvue were worth $5,499,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of KVUE. Manchester Capital Management LLC lifted its holdings in shares of Kenvue by 80.8% in the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the last quarter. Planned Solutions Inc. purchased a new position in shares of Kenvue during the 4th quarter worth $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Kenvue in the 4th quarter worth $28,000. Mather Group LLC. purchased a new position in shares of Kenvue in the 1st quarter worth $28,000. Finally, Oakworth Capital Inc. purchased a new position in shares of Kenvue in the 1st quarter worth $31,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Down 1.3 %

KVUE stock traded down $0.24 during trading hours on Tuesday, reaching $17.99. 6,708,195 shares of the stock were exchanged, compared to its average volume of 19,181,814. The firm’s 50-day moving average is $18.78 and its 200-day moving average is $19.62. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.23. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68. The company has a market cap of $34.45 billion, a price-to-earnings ratio of 23.17, a PEG ratio of 2.00 and a beta of 1.41.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.25 by $0.03. The company had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $3.79 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm’s quarterly revenue was down 24.9% compared to the same quarter last year. On average, equities research analysts expect that Kenvue Inc. will post 1.13 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th were issued a $0.20 dividend. The ex-dividend date was Tuesday, May 7th. This represents a $0.80 annualized dividend and a yield of 4.45%. Kenvue’s payout ratio is 102.56%.

Analyst Upgrades and Downgrades

KVUE has been the subject of several recent research reports. William Blair started coverage on Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating for the company. HSBC raised their target price on Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. Citigroup lowered their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. JPMorgan Chase & Co. decreased their price target on Kenvue from $23.00 to $22.00 and set an “overweight” rating for the company in a research note on Monday. Finally, Sanford C. Bernstein started coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target for the company. One analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $22.82.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.